StockNews.AI
SRRK
StockNews.AI
13 days

Scholar Rock Reports Second Quarter 2025 Financial Results and Highlights Business Progress

1. Scholar Rock's BLA for apitegromab is on track for September 22 review. 2. Urgent preparations indicate confidence in meeting regulatory deadlines and future sales.

Earnings
-15.14%Current Return
VS
+0.21%S&P 500
$36.9808/06 07:14 AM EDTEvent Start
$31.38208/07 02:24 PM EDTLatest Updated
2m saved
Insight
Article

FAQ

Why Bullish?

The upcoming PDUFA date signifies potential approval, which historically drives stock prices up.

How important is it?

Positive momentum leading to the PDUFA date increases the likelihood of investor sentiment turn.

Why Short Term?

The September PDUFA date creates immediate investor interest and potential stock volatility based on approval results.

Related Companies

SRRKSMABIIB
CAMBRIDGE, Mass.--(BUSINESS WIRE)--August 6, 2025-- Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy (SMA) and other severe and debilitating neuromuscular diseases, today reported financial results and updates for the second quarter ended June 30, 2025. “Our BLA is progressing under priority review towards our September 22 PDUFA date, and our team is working with urgency to prepare.

Related News